对于阿尔茨海默病的治疗目标:全蛋白质组门德尔随机化和协同化分析分析
Kefu Yu1, Ruiqi Jiang1,2, Dabiao Zhou3
1Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Journal of Alzheimer's disease : JAD
|June 2, 2025
概括
这项研究使用了门德尔的随机化来找到新的阿尔茨海默病 (AD) 药物标. 格拉努林 (GRN) 和补充受体1 (CR1) 在阿尔茨海默氏症治疗中表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种重要的神经退行性疾病,治疗方法很少.
- 确定新的治疗点对于推进AD治疗策略至关重要.
研究的目的:
- 为了确定阿尔茨海默病 (AD) 的新疗法目标.
- 利用全蛋白质组的门德尔随机化 (MR) 和局部化分析来发现潜在的药物标.
主要方法:
- 使用来自UKB-PPP和deCODE健康研究的GWAS数据进行了大规模的蛋白质组范围MR.
- 采用局部化分析来确认已识别的蛋白质-AD关联的共同因果变异.
- 进行了全现象关联研究 (PheWAS) 和药物重定向分析.
主要成果:
- 在两个数据集中,确定了基因预测的血蛋白水平和AD风险之间的显著关联.
- 四种蛋白质 (BCAM,CD55,CR1,GRN) 显示出一致的关联.
- 强有力的证据表明GRN,CR1和AD之间有共同的因果变异;确定了针对GRN和CR1的现有药物.
结论:
- 粒素 (GRN) 和补充受体1 (CR1) 被确定为阿尔茨海默病的有希望的治疗点.
- 这些发现为AD药物开发提供了新的途径.
- 需要进一步的研究和临床试验来验证这些目标.
更多相关视频
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.1K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
相关概念视频
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:26Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686